{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer+Non-Metastatic&page=2",
    "query": {
      "condition": "Prostate Cancer Non-Metastatic",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Prostate+Cancer+Non-Metastatic&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T22:56:02.414Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01083368",
      "title": "Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "polymorphism analysis",
          "type": "GENETIC"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 22,
      "start_date": "2009-01",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2019-08-21",
      "last_synced_at": "2026-06-10T22:56:02.414Z",
      "location_count": 3,
      "location_summary": "Cleveland, Ohio • Willoughby Hills, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Willoughby Hills",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01083368"
    },
    {
      "nct_id": "NCT03829436",
      "title": "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatocellular Carcinoma",
        "Metastatic Castration Resistant Prostate Cancer",
        "Renal Cell Carcinoma",
        "Non-small Cell Lung Cancer",
        "Colorectal Cancer",
        "Squamous Cell Carcinoma of Head and Neck",
        "Triple-Negative Breast Cancer",
        "Urothelial Carcinoma",
        "Cholangiocarcinoma",
        "GastroEsophageal Cancer",
        "Pancreatic Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "Part 1 TPST-1120",
          "type": "DRUG"
        },
        {
          "name": "Part 2 TPST-1120 + nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Part 3 TPST-1120",
          "type": "DRUG"
        },
        {
          "name": "Part 4 TPST-1120 + nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tempest Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 38,
      "start_date": "2019-03-20",
      "completion_date": "2022-09-07",
      "has_results": false,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-06-10T22:56:02.414Z",
      "location_count": 11,
      "location_summary": "San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03829436"
    },
    {
      "nct_id": "NCT00003626",
      "title": "Dolastatin 10 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "dolastatin 10",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": null,
      "start_date": "1998-10",
      "completion_date": "2000-05",
      "has_results": false,
      "last_update_posted_date": "2013-04-05",
      "last_synced_at": "2026-06-10T22:56:02.414Z",
      "location_count": 3,
      "location_summary": "Denver, Colorado • Detroit, Michigan • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003626"
    },
    {
      "nct_id": "NCT00511576",
      "title": "Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Lung Cancer",
        "Pulmonary Cancer",
        "Non-Small-Cell Lung Carcinoma",
        "Prostate Cancer",
        "Prostatic Cancer",
        "Gastric Cancer",
        "Stomach Cancer"
      ],
      "interventions": [
        {
          "name": "MGCD0103 & Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mirati Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2007-08",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-06-10T22:56:02.414Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00511576"
    },
    {
      "nct_id": "NCT00118092",
      "title": "17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Prostate",
        "Recurrent Prostate Cancer",
        "Stage IV Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "tanespimycin",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 17,
      "start_date": "2005-01",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2017-04-18",
      "last_synced_at": "2026-06-10T22:56:02.414Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00118092"
    },
    {
      "nct_id": "NCT01325558",
      "title": "A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Malignant Neoplasm",
        "Malignant Solid Tumour"
      ],
      "interventions": [
        {
          "name": "ALT-836 in combination with gemcitabine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Altor BioScience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2011-05",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2016-07-15",
      "last_synced_at": "2026-06-10T22:56:02.414Z",
      "location_count": 4,
      "location_summary": "Atlanta, Georgia • Iowa City, Iowa • Rochester, New York + 1 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01325558"
    },
    {
      "nct_id": "NCT06451497",
      "title": "This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Pancreas Adenocarcinoma",
        "Biliary Tract Cancer",
        "Prostate Cancer",
        "Urothelial Carcinoma",
        "Colorectal Cancer",
        "Triple Negative Breast Cancer",
        "High Grade Ovarian Serous Adenocarcinoma",
        "Diffuse Large B Cell Lymphoma",
        "Renal Cell Cancer Metastatic"
      ],
      "interventions": [
        {
          "name": "ZM008",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Zumutor Biologics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2024-05-22",
      "completion_date": "2027-04",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-06-10T22:56:02.414Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Austin, TX 78758, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Austin, TX 78758",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06451497"
    },
    {
      "nct_id": "NCT02566772",
      "title": "Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "TAS3681",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taiho Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 130,
      "start_date": "2016-03",
      "completion_date": "2024-04-26",
      "has_results": false,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-06-10T22:56:02.414Z",
      "location_count": 11,
      "location_summary": "Sacramento, California • Sarasota, Florida • Tampa, Florida + 8 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Jackson",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02566772"
    },
    {
      "nct_id": "NCT03460977",
      "title": "A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer (mCRPC)",
        "Small Cell Lung Cancer (SCLC)",
        "Follicular Lymphoma (FL)"
      ],
      "interventions": [
        {
          "name": "Mervometostat (PF-06821497)",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 453,
      "start_date": "2018-04-17",
      "completion_date": "2029-07-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-06-10T22:56:02.414Z",
      "location_count": 45,
      "location_summary": "Tucson, Arizona • Anaheim, California • Duarte, California + 22 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03460977"
    },
    {
      "nct_id": "NCT05283330",
      "title": "Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Breast Cancer",
        "Colon Cancer",
        "NSCLC",
        "mCRPC (Metastatic Castration-resistant Prostate Cancer)",
        "Glioblastoma",
        "Nonsmall Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "²¹²Pb-DOTAM-GRPR1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Orano Med LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2022-12-22",
      "completion_date": "2032-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-06-10T22:56:02.414Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Lexington, Kentucky • Glen Burnie, Maryland + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05283330"
    }
  ]
}